Chamber of Commerce numbery
(Kamer van Koophandel-NL)
09165918
The Steering Committee (SC) consists of the Chair of the EAPCRI (Peter Donnelly), the secretary (Jurgen Loeffler) who is also chair of the laboratory Working Party (LAB WP) and the Treasurer (Rosemary Barnes) who is also Chair of the Clinical Working Party (CLIN WP). In addition we have initiated a Statistical Working Party (STATS WP) which is Chaired by Peter Donnelly and includes the SC and Mario Cruciani (Verona) and Carlo Mengoli (Padua). Its task is to manage the statistical analyses as required by the LAB WP.
The Steering Committee is charged with managing the business of the EAPCRI including funding. It meets 2-3 a year to review the progress of the EAPCRI, plan and coordinate its activities and ensure the minutes and accounts are in order. In addition the SC communicates directly with other academic groups as well as with commercial companies who has similar interests as the EAPCRI. The SC also identifies opportunities for the EAPCRI to present its work at national and international forums.
J Peter Donnelly PhD.Dr. Donnelly is Coordinator of Studies in Supportive Care of the Department of Haematology and is a member of the Nijmegen Institute for Infection Inflammation and Immunity.
He is Chair of the EORTC Infectious Disease Group and member of the EBMT Infectious Diseases Working Party and EUCAST subcommittee on Antifungal Susceptibility Tests. His current research interests are the epidemiology, diagnosis and management of invasive fungal diseases, mucosal barrier injury and infection and infectious complications of the neutropenic patient.
Dr Rosemary A Barnes MA, MD, FRCP, FRCPathRosemary Barnes is Clinical Reader in Medical Microbiology and acting head of the Department of Infection, Immunity and Biochemistry at the School of Medicine at Cardiff University.
She qualified from Cambridge University and Westminster Medical School.
Her research interests include infections in immunocompromised patients. A particular focus is the rapid diagnosis of invasive fungal infection and the impacts this has on the optimal use of antifungal agent and patient outcomes.
PD Dr. rer. nat. Juergen Loeffler, Ph. D.Go to the Closed Section